OrbiMed is a global healthcare investment firm founded in 1989 and based in New York, with a worldwide presence that includes offices in several regions. It allocates capital across private equity, venture capital, and public equity to support healthcare companies at various stages, from startups to established firms. Its focus spans biopharmaceuticals, medical devices, diagnostics, life sciences tools, and digital health, as well as healthcare services. The firm pursues opportunities across major markets in North America, Europe, and Asia, often leveraging region-specific teams to invest in companies in Israel, China, India, South Korea, and other jurisdictions. OrbiMed emphasizes building world-class companies by providing strategic financing, industry expertise, and global resources to portfolio companies in pursuit of medical breakthroughs and sustainable growth.

RA Capital Management is a Boston-based investment management firm specializing in growth-oriented and early-stage support for healthcare, life sciences, and planetary health companies. The company deploys capital across private seed rounds, series financings, and public markets, with a focus on drugs, medical devices, diagnostics, and tools that advance patient care. It leverages a science-driven approach through its research platform TechAtlas and provides value-added services such as board representation, executive recruitment, and market intelligence to portfolio companies. The firm operates an incubator program called Raven to nurture biomedical innovation and maintains an Innovator Resources program to guide company development. RA Capital emphasizes evidence-based investing, long-term partnerships, and social responsibility, aiming to drive value creation from inception through commercialization.

Qiming Venture Partners is a China-based venture capital firm founded in 2006, with offices in Shanghai, Beijing, Suzhou, Hong Kong and Singapore. It backs early and growth-stage technology, consumer and healthcare companies, applying deep industry knowledge and hands-on support to help portfolio companies scale. The firm manages US-dollar and RMB funds and maintains a global footprint, including a dedicated US arm, Qiming Venture Partners USA, to pursue cross-border opportunities in healthcare, therapeutics and digital health. Since inception, it has invested in more than 530 companies and achieved more than 200 exits via IPOs, M&A or other means, with over 70 portfolio companies reaching unicorn or super unicorn status. Qiming emphasizes long-term partnerships with entrepreneurs, aligning resources and networks to drive innovation and societal progress across its portfolio.

Eli Lilly and Company is a global biopharmaceutical company engaged in discovering, developing, manufacturing, and marketing medicines across neuroscience, cardiometabolic, cancer, and immunology. The company operates manufacturing and distribution facilities in the United States, Puerto Rico, and multiple countries, with products sold in about 135 markets worldwide. Through ongoing research and development, Lilly aims to deliver therapies that improve patient outcomes and access to medicines. Its portfolio includes treatments such as Mounjaro and Jardiance for cardiometabolic diseases, Verzenio and Jaypirca for cancer, Trulicity and Humalog for diabetes, and Taltz and Olumiant for immunology, among others. Lilly emphasizes safety and quality in manufacturing and supports patients through educational and support initiatives, reflecting a long history of pharmaceutical leadership and a commitment to advancing personalized medicine.

SOSV is a global venture capital firm founded in 1995 and headquartered in New Jersey. The firm focuses on seed-to-growth investments in deep tech sectors, including biotech and life sciences, hardware and robotics, and cross-border software with emphasis on markets in Asia. It supports startups from early stages with investment capital as well as resources such as laboratories, collaborative spaces, and expert mentorship to accelerate product development and market traction. SOSV operates purpose-built programs to help portfolio companies raise follow-on funding, scale operations, and reach customers, often through structured matchmaking and access to a global network of investors. With a broad portfolio spanning hundreds of companies worldwide, SOSV aims to foster innovation, build vibrant entrepreneurial ecosystems, and contribute to sustainable technological advancement.

Founded in 2020, the European Innovation Council is a Brussels-based venture capital initiative that supports top innovators, entrepreneurs, small companies, and researchers with bright ideas. It co-invests with private investors in early-stage startups, prioritizes deep technology ventures, and pursues ESG-positive impacts to accelerate commercialization and scale-up.

Novo Nordisk is a global healthcare company focused on discovering, developing, and delivering medicines for serious chronic diseases, with a core emphasis on diabetes care. The organization produces and distributes insulin and other therapies aimed at treating diabetes and related conditions, while investing heavily in scientific research and biopharmaceutical innovation. Through partnerships and sustained commitments to accessibility, Novo Nordisk seeks to improve patient outcomes and support health systems worldwide. The company operates across many markets, supported by its production of insulin pens and a broad portfolio addressing obesity, rare blood and endocrine disorders, and other chronic diseases. It pursues long-term social responsibility and sustainability as integral to its business model.

Morningside Group is a venture capital firm founded in 1986, originally established as a family office for the Chan family, and is based in the greater Boston area. The firm makes venture investments in companies with novel science and technology, pursuing a long-term, patient approach to company-building and emphasizing ethical practices. Its investment focus spans life sciences, digital health, artificial intelligence, materials science, and information technology. In addition to its investment activities, Morningside supports charitable initiatives in education, research, and healthcare, with partnerships including the Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design.

New Enterprise Associates is a venture capital firm founded in 1977 and based in Menlo Park, California, with a global investment reach. It provides capital and operational support to early, growth, and later-stage companies across a wide range of industries, including software, consumer technology, healthcare technology, life sciences, energy technology, infrastructure, and AI-enabled services. NEA collaborates with founders to address technical challenges, guide product development, and expand markets, leveraging its domain expertise to help portfolio companies scale from seed stages through IPO. The firm invests across the United States, Asia, and other regions, often supporting companies from early stages to scale, and has a long track record that includes numerous IPOs and acquisitions. NEA emphasizes a hands-on partnership approach and seeks opportunities across sectors that enable transformational businesses through technology and data-driven innovation.

Founded in 1985, The Invus Group is a global private equity firm that partners with entrepreneurs, founders and management teams across the company lifecycle. Blending a family-office approach with multi-strategy investing, it supports transformative growth in sectors including consumer products and services, technology, life sciences, software, agtech, industrials, education and medical devices. The firm pursues long-term value creation through strategic insight, capital and execution, investing in companies from early stages to mature businesses and providing both lead investments and co-investments in private transactions worldwide. It maintains a global footprint with offices in New York, London, Paris and Hong Kong and has a flexible structure designed to align incentives with partners over time.

Venrock is a venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. Based in Palo Alto, California, with offices in New York City, it specializes in seed and early-stage investments across technology and healthcare, including information technology, software, cybersecurity, genomics, and digital health. The firm supports entrepreneurs with capital, strategic guidance, and access to its network to help build enduring companies. Notable portfolio entries include Apple, Illumina, Gilead Sciences, Intel, Nest, Endeca, and SlideShare, reflecting a history of backing influential technology and life sciences ventures.

ARCH Venture Partners is a Chicago-based venture capital firm founded in 1986 that concentrates on science-driven startups, especially in life sciences, biotechnology, healthcare, and related technologies. It backs companies co-founded by scientists and entrepreneurs and supports commercialization of innovations developed at academic research institutions and national laboratories. The firm takes a long-term, hands-on approach, leveraging its network to assist portfolio companies from inception to market realization and to build transformative enterprises. ARCH has raised ten venture funds totaling over $3 billion and has invested in more than 150 companies worldwide, reflecting a focus on strategic value creation and governance.

Deerfield Management is a New York-based healthcare investment firm focused on long-term, structured investments in public and private healthcare companies. Founded in 1994, it manages a diversified portfolio spanning therapeutics, medical devices, diagnostics, digital health, and health services. The company combines investment activity with information services and philanthropy, leveraging Deerfield Intelligence, an approach that uses AI, data, and market research to inform decisions. It supports innovation through initiatives such as Deerfield Discovery and Development and the Deerfield Foundation, which aims to improve children's health worldwide. Through its capital and strategic insight, Deerfield seeks to connect capital, ideas, and technology to advance human health.

General Catalyst is a venture capital firm founded in 2000 and based in Cambridge, Massachusetts, with additional offices in North America and Europe. It provides seed to growth-stage investments in technology companies, with emphasis on software, consumer and enterprise applications, fintech, crypto, health tech, and AI-enabled businesses. The firm supports portfolio companies with capital, strategic guidance, mentorship and operational assistance to help them scale and innovate across industries, including healthcare, fintech and consumer technology. General Catalyst manages multiple venture funds and pursues both early-stage and growth investments, often taking minority to majority equity positions. The firm has a global reach and a history of backing companies that become industry leaders, with ongoing focus on resilience and applied AI.

Alumni Ventures is a venture capital firm founded in 2014 and based in Manchester, New Hampshire. It connects accredited individual investors with startup deals and co-invests alongside established venture capital firms across multiple stages, from seed to growth. The firm provides access to diversified portfolios through funds, syndicates, and investing clubs, supported by a large network of community members and individual investors. It invests across sectors and geographies, with a focus on transparency and due diligence in collaborative investments with leading firms such as Andreessen Horowitz, Sequoia, and Y Combinator. Alumni Ventures operates internationally with offices in New York, Boston, Menlo Park, Chicago, London, and Tokyo and has raised substantial capital to back founders with strategic capital and resources.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and headquartered in San Francisco, with offices in Canada, the United States, and Europe. The firm invests across the healthcare sector at all stages, with emphasis on the discovery and development of novel therapeutics, including pharmaceuticals, biotechnology, medical devices, and life sciences. Versant combines investment, operating, and scientific expertise to support portfolio companies through strategic guidance and hands-on involvement in company building. The firm manages substantial capital, enabling a hands-on approach to helping entrepreneurs build durable companies addressing high unmet medical needs.

Alexandria Venture Investments is the strategic venture capital arm of Alexandria Real Estate Equities. It provides seed through growth capital to life science and technology companies developing breakthrough therapies, diagnostics, research tools, agrifoodtech, agtech, digital health, and related platforms. Backed by the parent company’s industry experience and scientific advisory network, the firm leverages long-standing relationships and domain expertise to support early to growth-stage ventures aiming to translate scientific advances into practical healthcare and technology solutions.

F-Prime Capital is a venture capital firm based in Cambridge, Massachusetts, with a long history of investing in healthcare and technology companies. It backs early-stage and growth companies across life sciences, including therapeutics, medtech, and healthtech, and technology sectors such as enterprise software, fintech, frontier tech, and crypto, with a global reach across the Americas, Europe, and Asia. The firm manages about 4.8 billion in capital and relies on a multidisciplinary team of scientists, engineers, physicians, operators, and investors to help portfolio companies accelerate scalable growth. It also provides advisory support, leveraging deep sector expertise and operational experience to guide portfolio companies toward meaningful breakthroughs.

Vivo Capital is a global healthcare investment firm founded in 1996 and based in Palo Alto, California, with offices in Asia. It operates a multi-fund platform spanning growth equity, private equity including buyouts, venture capital, and public equity, and invests broadly in biotechnology, pharmaceuticals, medical devices, and healthcare services across major markets. The firm pursues opportunities worldwide, supporting companies at various development stages with a team of physicians, scientists, entrepreneurs, operating executives, and industry experts who contribute deep sector insight. It manages approximately $5.8 billion in assets under management.

Ben Franklin Technology Partners of Southeastern Pennsylvania is a nonprofit organization founded in 1982 that strengthens the Philadelphia region's technology ecosystem by providing capital, strategic guidance, and professional connections to technology startups and growth companies across Philadelphia, Bucks, Delaware, Chester, and Montgomery counties. It serves as a seed-stage capital provider and investor across information technology, health, and physical sciences, advancing technology commercialization through university–industry partnerships and regional initiatives. The organization aims to accelerate innovation, create jobs, and build a robust entrepreneurial community by offering funding, mentorship, and access to a broad network of resources.

Samsara BioCapital is a venture capital firm based in Palo Alto, California, that invests in biotechnology and healthcare companies across the United States. The firm supports biotech ventures by providing capital and strategic guidance to help advance innovative therapies and discoveries. It operates as a registered investment adviser, offering investment advisory services to entrepreneurs and venture teams as they work to bring new biotech solutions to market.

High-Tech Gründerfonds is a Germany-based venture capital firm established in 2005 that funds early-stage technology startups in Germany. Based in Bonn with an office in Berlin, it supports companies across software, information technology, digital and industrial tech, life sciences, chemistry, IoT, energy, and related fields by providing initial capital and subsequent funding, complemented by active guidance from investment managers. The firm typically acts as a lead investor and cooperates with other investors to help portfolio companies advance from concept to market, with a focus on startups that have begun commercial operations. By combining financing with hands-on support, HTGF aims to help high-potential founders develop their technology, validate products, and scale within the German market.

Khosla Ventures is a California-based venture capital firm founded in 2004 and headquartered in Menlo Park. It provides capital and strategic guidance to technology companies across stages, investing in sectors including artificial intelligence, digital health, sustainability, climate tech, and consumer technology. The firm seeks startups with innovative technologies or business models and offers hands-on support to help build enduring companies. It manages multiple funds and runs initiatives such as Khosla Impact, which supports high-impact for-profit ventures addressing the needs of low-income populations and emerging markets. Through funding and guidance, it backs transformative technologies and scalable businesses in the United States and globally.

Redmile Group is a San Francisco-based investment firm focused on healthcare, including life sciences and oncology; it engages in venture, growth and crossover investing and operates an office in New York.

Mission BioCapital is a life sciences venture capital firm established in 2009 and based in Cambridge, Massachusetts, that funds early-stage biotechnology companies and supports them through clinical development. The firm emphasizes mentorship and practical assistance, offering entrepreneurs access to laboratory space, incubator networks, and programs designed to accelerate progress and secure follow-on funding. Its approach combines capital with hands-on guidance across discovery, development, and commercialization, leveraging a history of supporting dozens of startups. Through a broad ecosystem in the United States and Europe, Mission BioCapital aims to translate scientific discoveries into tangible solutions by pairing funding with operational support, expert advice in areas such as drug discovery, legal, and accounting, and strategic mentorship to help portfolio companies reach milestones and attract subsequent investment.

Pfizer is a global pharmaceutical company that develops, manufactures, and sells medicines and vaccines across a broad range of therapeutic areas. It aims to provide safe, effective, and affordable health care solutions and services that support wellness, prevention, and treatment. The company maintains a substantial portfolio of prescription medicines and vaccines and pursues a robust pipeline of new products and technologies intended to address major diseases, including cancer and neurodegenerative conditions. Pfizer conducts business worldwide, with a significant share of international sales and a broad geographic footprint. Founded in 1849 and headquartered in the United States, Pfizer focuses on research and development, manufacturing scale, and strategic collaborations to improve patient outcomes and expand access to therapies.

Sofinnova Partners is an independent venture capital firm based in Paris, France, focusing on life sciences. It finances start-ups, early-stage companies, corporate spin-offs, and occasional turnarounds in biopharmaceuticals, biotech, medical devices, and related areas. The firm often acts as a lead or cornerstone investor and is frequently the first institutional backer in Series A rounds, maintaining an active role including board seats from formation through exit. It pursues global opportunities and emphasizes thorough due diligence on portfolio companies, including management and intellectual property considerations. The firm was established in 1972.

Andreessen Horowitz is a Menlo Park, California-based venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz. It backs technology companies across stages, from seed to growth, with a broad focus on software, cloud infrastructure, enterprise software and services, fintech, consumer internet, artificial intelligence, biotechnology, and life sciences applications at the intersection of computer science and biology. The firm emphasizes long-term support for entrepreneurs, offering capital and resources to help companies scale, and operates through multiple investment vehicles to fund early and later-stage opportunities. Its portfolio targets information technology, software-enabled businesses, and technology-enabled services, reflecting a commitment to innovation and leadership in American technology.

Polaris Partners is a Boston-based venture capital firm, founded in 1996, that backs technology and life science companies across the United States and Europe. The firm invests across stages, from founding to profitable growth, with a focus on sectors including software, healthcare information technology, digital health, life sciences, biotechnology, and genomics. Polaris Partners partners with repeat entrepreneurs and supports portfolio companies with strategic guidance, operating help, and resources to accelerate growth. The firm maintains offices in Boston and San Francisco and administers affiliate funds to structure its portfolio, including Polaris Innovation Fund and Polaris Growth Fund, reflecting long-term partnerships with founders and teams to bring transformative therapies and technologies to market.

8VC is a San Francisco-based technology and life sciences investment firm that partners with founders to develop transformative technologies and create long-term economic and societal value. The firm pursues investments across sectors including healthcare, energy, consumer goods, financial services, information technology, manufacturing, enterprise software, logistics, and cybersecurity, and across stages from seed to later rounds. It emphasizes long-term partnerships and supports portfolio companies through programs such as fellowships and community-building efforts that foster collaboration and growth. 8VC seeks to back companies leveraging breakthrough technologies to address critical challenges and drive innovation, aiming to generate durable value for founders and stakeholders.

Legend Capital is a Beijing-based venture capital firm and the investment arm of Legend Holdings, founded in 2001 to back high-growth technology and related companies in China and markets connected to China. The firm concentrates on early-stage IT, telecommunications, media, healthcare, consumer services, modern services, and sectors such as infrastructure, clean technology, and advanced manufacturing. It provides portfolio companies with strategic resources, market access support, and tailored services to help with business development, branding, and navigating the Chinese market, aiming to create value and maximize returns for investors.

HBM Healthcare Investments is a Swiss investment firm founded in 2001 that focuses on delivering access to a globally diversified portfolio of healthcare companies. Headquartered in Switzerland, the firm targets opportunities across human medicine, biotechnology, medical technology and diagnostics, investing in both private and public companies with established or near-market products. It emphasizes active portfolio management and provides strategic guidance to portfolio companies to support value creation. By leveraging demographic trends and medical innovation, the firm seeks attractive returns while maintaining a diversified asset mix that includes private holdings, public equities and funds. The company is noted for an attractive dividend policy with a yield around five percent.

Deep Track Capital is a Greenwich, Connecticut-based venture capital investment firm that concentrates on life sciences and biotechnology. It partners with management teams of innovative public and pre-IPO biotech companies, offering capital, strategic guidance, and access to its industry network. The firm aims to lead transactions, build large syndicates, and participate in rounds led by other investors, leveraging expertise in healthcare finance, biotech investing, and drug development to support portfolio companies through development and growth.

Forbion is a global venture capital firm based in Naarden, Netherlands, focused on biotech innovations and sustainable solutions to improve human and planetary health. It invests across human health, planetary health and the bioeconomy, spanning pre-clinical, early clinical and growth stages, and combines company building with venture capital while integrating ESG principles. With two decades of experience and about €5 billion under management across 11 funds, Forbion backs companies in Europe and North America across life sciences, pharmaceuticals and biotechnology sectors.

Korea Investment Partners is a Seoul-based venture capital and private equity firm with more than 30 years of experience backing bold entrepreneurs. It manages multiple venture and private equity funds with about US$1.8 billion in assets under management and operates globally from its Seoul headquarters, with offices in Shanghai, Beijing, and Sunnyvale. The firm invests across B2B, media, healthcare, information technology, manufacturing, life sciences including oncology, mobile, infrastructure, and augmented reality. It has backed notable companies such as Kakao, Naver, YG Entertainment, Bodyfriend, Osstem Implant, DoubleU Games, and Didi Chuxing. Korea Investment Partners focuses on supporting scalable business models and creating long-term value for portfolio companies and investors through strategic partnerships and global growth.

Kurma Partners is a Paris-based investment firm focused on financing innovation in healthcare and biotechnology across development stages, from early discovery to later-stage growth. It backs therapeutics, diagnostics, health technology, and digital health ventures in Europe, leveraging ties with research centers and hospitals to translate scientific advances into clinical and commercial success. The firm operates with a Europe-wide reach, with a notable presence in France, and emphasizes collaborating with researchers and entrepreneurs to support impactful, sustainable healthcare solutions.

Antler is a global venture capital firm founded in 2017 and based in Singapore that invests in technology companies and incubates startups across diverse sectors. It supports founders from day one with a worldwide community of co-founders, access to talent, expert advisors, and expansion support, complemented by capital to help launch and scale ventures. Through regional funds and programs, Antler backs early-stage ventures across geographies, facilitating collaboration among founders and providing resources to help teams recruit, validate ideas, and enter markets.

IMM Investment is a private equity and venture capital firm based in Seoul, South Korea, established in 1999. It operates as an asset manager focusing on mezzanine, venture capital, and infrastructure investments, with sectors including information technology, healthcare/biotech, and manufacturing. The firm targets midsize companies in South Korea and engages in mergers and acquisitions, corporate restructuring, cross-border investments, and co-investments, often taking an active management role. It also operates IMM Investment Hong Kong, which pursues venture capital, growth equity, infrastructure, and cross-border investment strategies.

SV Health Investors is a US-headquartered private equity and venture capital firm focused on healthcare and life sciences. Formerly known as SV Life Sciences, it invests in therapeutics, biotechnology, medtech, and healthcare growth companies across North America and Western Europe, with offices in Boston, San Francisco, and London. Founded in 1993, the firm aims to transform healthcare by backing entrepreneurs who develop breakthrough treatments and technologies, supported by a team of investment professionals and operating partners. It has managed billions of dollars in capital across private healthcare funds, pursuing a strategy that combines early-stage and growth investments and seeks value through strategic partnerships, acquisitions, and, when appropriate, public offerings. The firm operates as a dedicated partner to innovators in the sector, helping translate scientific advances into patient impact and commercial success.

IP Group is a global science and technology investment company focused on identifying, backing, and growing early‑stage, science‑based businesses. It commercialises intellectual property originating from research‑intensive institutions, managing the process from IP discovery to business development or the formation of strategic partnerships. The firm concentrates on HealthTech, DeepTech, and CleanTech, backing university spin‑outs and other innovative ventures with the potential to disrupt markets and deliver strong financial returns while delivering social and environmental impact aligned with the UN Sustainable Development Goals. IP Group leverages expertise in investment case development, governance, results reporting, and regulatory affairs, and cultivates collaborations with leading research institutions to accelerate growth. As a catalyst for innovation, it provides capital, strategic guidance, and operational support to portfolio companies to translate scientific advances into scalable technologies that benefit society and the economy.

Takeda is a global biopharmaceutical company focused on developing and delivering medicines across oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. It researches, develops, manufactures, markets, and sells pharmaceutical drugs and vaccines to improve patient health worldwide. The company maintains a diversified geographic footprint, with substantial activity in the United States, Japan, Europe and Canada, and operates a broad portfolio of therapies designed to address unmet medical needs. Takeda emphasizes research and development, pursuing innovation in gastrointestinal and inflammatory diseases, oncology, and neuroscience, while upholding commitments to patient outcomes, ethical practices, and sustainability. It is Japan’s largest pharmaceutical company by several metrics.

Right Side Capital Management is a San Francisco-based venture capital firm that focuses on early-stage technology companies, emphasizing capital-efficient startups across the United States and Canada. The firm targets pre-product-market-fit ventures and typically funds rounds in the tens of thousands to low hundreds of thousands of dollars, with round sizes commonly ranging from 50K to 500K. It employs a data-driven, rapid decision process and makes a high volume of investments annually, aiming to provide a firm yes or no within roughly two weeks. The team comprises seasoned founders who bring hands-on experience, and the firm operates like an operating company, delivering post-investment support and broad diversification across a large portfolio. Its activity spans multiple states beyond traditional hubs, reflecting a broad geographic reach and an emphasis on backing entrepreneurs overlooked by mainstream venture capital.

Keiretsu Forum is a global investment community of accredited private equity investors, venture capitalists, and corporate/institutional investors. It operates as an international network with chapters in numerous regions, connecting members through private equity funding, deal flow, and related activities. Members review opportunities presented through restricted forums and may invest in selected companies. The organization supports collaboration by providing access to capital, resources, and mentoring through its events and partnerships.

Logos Capital is a biotechnology-focused investment firm headquartered in San Francisco. The company applies disciplined, data-driven diligence across medical, scientific, and clinical disciplines to identify transformative therapies in healthcare. By combining in-house analytics with rigorous clinical evaluation, Logos Capital seeks to back life-changing therapeutics with strong value propositions. The firm emphasizes rigorous opportunity identification, thorough clinical trial underwriting, and proactive risk management, leveraging advanced analytics to predict trial outcomes and support informed investment decisions. Its approach aims to deliver compelling returns while contributing to patient outcomes by supporting companies with transformative technologies.

European Investment Fund is the EU's financing arm for small and medium-sized enterprises and mid-caps, providing financial instruments to improve access to affordable financing for businesses across their lifecycle, with a focus on innovation, growth, competitiveness, social impact and sustainability. The EIF leverages its capital base to foster public-private partnerships and allocates guarantees and equity funding to catalyze lending and investment for startups and small businesses throughout Europe, including EU member states, candidate countries and EFTA countries. It collaborates with partners to close funding gaps and support entrepreneurship and economic resilience.

SR One is the corporate venture capital arm of GlaxoSmithKline. It invests globally in emerging life science companies pursuing innovative science with potential to significantly improve medical care. The firm adopts a back-and-build approach, supporting founders and entrepreneurs to translate scientific discoveries into new medicines. With a transatlantic presence on the West Coast of the United States and London, SR One provides geographic reach, expertise, and timely business support to its portfolio. Since 1985, SR One has invested about 800 million across more than 180 companies.

Sofinnova Investments is a venture capital firm founded in 1976 and headquartered in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It backs life sciences and information technology companies across the United States and Europe, from seed through early and growth stages. In life sciences, it targets clinical-stage pharmaceutical and biotechnology companies, drug discovery platforms, and medical technology addressing diseases with unmet medical needs, including oncology, respiratory, dermatology, ophthalmology, neurology and women's health. In information technology, it supports product-oriented software, enterprise IT solutions and telecommunications infrastructure. The firm often requires board participation for early-stage lead or co-lead investments and emphasizes hands-on guidance to help entrepreneurs build global businesses.

TCG Crossover is a science-driven venture capital firm focused on healthcare and biotechnology. It invests in biotechnology and pharmaceutical companies across the United States and Europe, supporting the development of medicines through a network of scientific advisors and resources that help navigate clinical and regulatory challenges. The firm has teams in Palo Alto and New York City and pursues long-term partnerships with entrepreneurs to translate cutting-edge science into meaningful patient outcomes.

Casdin Capital is an investment firm focused on life sciences and healthcare. Founded in 2012 by Eli Casdin and based in New York, it seeks opportunities across the life sciences spectrum, including biotechnology, digital health, oncology, agtech, and healthcare services. The firm pursues early- to late-stage private investments and, at times, long-short equity strategies, leveraging data-driven insights, molecular information, and precision medicine to identify transformative opportunities. It emphasizes patient capital, disciplined investing, and strong collaborations to support companies advancing diagnostics, therapeutics, and sustainable solutions. By capturing and processing data to unlock breakthroughs, Casdin Capital backs teams with the potential to transform modern medicine.

Gaingels is a venture capital organization focused on supporting LGBTQ+ founders and leaders and their allies. It invests across stages and industries, building a global portfolio of 130+ companies and deploying around $70 million in capital. Beyond funding, Gaingels helps portfolio companies recruit diverse C-suite and board talent and fosters a global community of investors, operators, and entrepreneurs working toward inclusive leadership and positive social change through business.